长风药业年度业绩预告:主力产品CF017均价下滑拖累盈利

美股速递
Mar 20

受核心产品CF017及其他主要药品平均售价下调影响,长风药业(CF Pharmtech)预计本财年盈利水平将面临下行压力。产品价格策略的调整虽有助于提升市场渗透率,但短期内将对整体营收规模及利润率产生显著冲击。

公司表示将持续优化生产成本结构,通过供应链协同与工艺创新抵消部分价格波动带来的负面影响。管理层强调将加速新品研发管线推进,以期通过产品组合升级重塑增长动能。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10